Hologic Inc. (NASDAQ:HOLX) VP Karleen Marie Oberton sold 3,023 shares of the business’s stock in a transaction that occurred on Monday, November 21st. The stock was sold at an average price of $38.32, for a total value of $115,841.36. Following the transaction, the vice president now owns 13,260 shares of the company’s stock, valued at $508,123.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Karleen Marie Oberton also recently made the following trade(s):

  • On Tuesday, November 15th, Karleen Marie Oberton sold 1,211 shares of Hologic stock. The stock was sold at an average price of $36.55, for a total value of $44,262.05.
  • On Tuesday, November 8th, Karleen Marie Oberton sold 984 shares of Hologic stock. The stock was sold at an average price of $38.57, for a total value of $37,952.88.
  • On Monday, November 7th, Karleen Marie Oberton sold 522 shares of Hologic stock. The stock was sold at an average price of $38.53, for a total value of $20,112.66.
  • On Monday, October 10th, Karleen Marie Oberton sold 31,470 shares of Hologic stock. The stock was sold at an average price of $40.00, for a total value of $1,258,800.00.

Hologic Inc. (NASDAQ:HOLX) traded down 0.47% during trading on Tuesday, hitting $38.47. 2,975,727 shares of the stock were exchanged. The firm has a market capitalization of $10.68 billion, a PE ratio of 33.16 and a beta of 1.13. The stock has a 50 day moving average price of $37.94 and a 200-day moving average price of $36.73. Hologic Inc. has a 12-month low of $31.84 and a 12-month high of $41.66.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.02. Hologic had a net margin of 11.68% and a return on equity of 26.76%. The firm had revenue of $726.80 million for the quarter, compared to analysts’ expectations of $721.52 million. During the same period last year, the firm earned $0.43 earnings per share. The business’s revenue for the quarter was up 3.4% on a year-over-year basis. On average, equities research analysts anticipate that Hologic Inc. will post $2.15 earnings per share for the current fiscal year.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

A number of institutional investors have recently made changes to their positions in the stock. Mizuho Asset Management Co. Ltd. boosted its position in shares of Hologic by 89.9% in the second quarter. Mizuho Asset Management Co. Ltd. now owns 3,313 shares of the company’s stock worth $115,000 after buying an additional 1,568 shares during the last quarter. J.Safra Asset Management Corp acquired a new position in shares of Hologic during the second quarter worth about $115,000. Invictus RG boosted its position in shares of Hologic by 577.0% in the second quarter. Invictus RG now owns 3,791 shares of the company’s stock worth $131,000 after buying an additional 3,231 shares during the last quarter. Global X Management Co. LLC boosted its position in shares of Hologic by 149.9% in the third quarter. Global X Management Co. LLC now owns 3,871 shares of the company’s stock worth $150,000 after buying an additional 2,322 shares during the last quarter. Finally, Thompson Siegel & Walmsley LLC boosted its position in shares of Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

HOLX has been the subject of a number of research analyst reports. BTIG Research upped their target price on Hologic from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, November 3rd. Needham & Company LLC restated a “hold” rating on shares of Hologic in a research report on Thursday, November 3rd. Leerink Swann restated a “top pick” rating and issued a $43.00 target price (down from $46.00) on shares of Hologic in a research report on Thursday, November 3rd. Zacks Investment Research downgraded Hologic from a “buy” rating to a “hold” rating in a research report on Monday, November 7th. Finally, Piper Jaffray Cos. set a $40.00 target price on Hologic and gave the stock a “hold” rating in a research report on Monday, July 25th. They noted that the move was a valuation call. Six investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $43.20.

COPYRIGHT VIOLATION NOTICE: “Hologic Inc. (HOLX) VP Karleen Marie Oberton Sells 3,023 Shares” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2016/11/22/hologic-inc-holx-vp-karleen-marie-oberton-sells-3023-shares.html.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

5 Day Chart for NASDAQ:HOLX

Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.